NCT06728410 2026-03-09
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Hoosier Cancer Research Network
Phase 2 Recruiting
Clinical Trials
4 trialsNCT07434843 2026-02-27
PEMIGIST
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT06906562 2026-02-17
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT05267106 2025-12-30
FIGHT-209
Incyte Corporation
Phase 2 Terminated